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Abstract 
Plants can provide a cost-effective and scalable technology for production of therapeutic 
monoclonal antibodies, with the potential for precise engineering of glycosylation. Glycan structures 
in the antibody Fc region influence binding properties to Fc receptors which opens opportunities for 
modulation of antibody effector functions. To test the impact of glycosylation in detail, on binding to 
human Fc receptors, different glycovariants of VRC01, a broadly-neutralising HIV monoclonal 
antibody, were generated in Nicotiana benthamiana and characterised. These include glycovariants 
lacking plant characteristic α1,3-fucose and β1,2-xylose residues and glycans extended with terminal 
β1,4-galactose. Surface plasmon resonance-based assays were established for kinetic/affinity 
evaluation of antibody - FcγR interactions, and revealed that antibodies with typical plant 
glycosylation have a limited capacity to engage FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa, however the 
binding characteristics can be restored and even improved with targeted glycoengineering. All plant-
made glycovariants had a slightly reduced affinity to the neonatal Fc receptor (FcRn) compared with 
HEK cell derived antibody. However, this was independent of plant glycosylation, but related to the 
oxidation status of two methionine residues in the Fc region. This points towards a need for process 
optimisation to control oxidation levels and improve the quality of plant-produced antibodies. 
 
Introduction  
Antibody-based therapeutics comprise a major segment of the fast-growing biopharmaceutical 
market. There are currently more than 50 monoclonal antibodies approved for clinical use and 
hundreds are in pre-clinical and clinical development (Ecker et al., 2015). Most of these are IgG 
antibodies that target cancer and autoimmune disorders, although there is growing interest in 
monoclonal antibodies to tackle infectious diseases (Irani et al., 2015). Whilst binding to cognate 
antigen is the hallmark of antibody function, engagement of cell-surface Fc receptors can activate 
immune cells to remove or neutralise antibody-coated targets via processes known collectively as 
antibody effector functions (Desjarlais and Lazar, 2011). There are six classical Fc receptors 
recognising IgG: high-affinity FcγRI (CD64) and low-affinity FcγRIIa, FcγRIIb, FcγRIIc (CD32a-c), 
FcγRIIIa and FcγRIIIb (CD16a and b), and their cooperation on immune cells surface allows for a 
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tailored cellular response against the target. Interaction of the antibody Fc region with FcγRs is 
influenced by glycans attached to a highly conserved N-glycosylation site within the Fc fragment and 
their composition can influence binding affinity and receptor-mediated activity (Jefferis, 2009c). 
 An important feature of IgG antibodies is their long serum half-life, which extends their 
therapeutic and protective effect (Ward et al., 2015). Rapid clearance of IgG from the circulation is 
prevented by interaction with neonatal Fc receptor (FcRn), which protects IgG antibodies from 
endosomal degradation (Junghans and Anderson, 1996). FcRn is a membrane heterodimer protein, 
which belongs to the MHC class I molecular family (Burmeister et al., 1994). Recent studies have 
demonstrated that efficacy of antibody therapy correlates with serum half-life and that engineering 
antibodies to prolong their lifespan in the blood extends their therapeutic effect(Ko et al., 2014; 
Zalevsky et al., 2010). 
 The importance of Fc receptor interactions was recently highlighted for broadly neutralising 
antibodies (bNAbs) in protection against HIV infection (Gautam et al., 2016; Ward et al., 2015). 
Various studies suggest that bNAbs can control persistent viral reservoirs, raising the possibility of 
their use for treating infected individuals (Caskey et al., 2015; Chun et al., 2014). Protective and 
therapeutic effects of antibodies are largely dependent on the antibody Fc region, and were 
dramatically decreased when FcR-binding activities were engineered out of the antibodies 
(Bournazos et al., 2014). The role of FcγRs in antibody-mediated protection against HIV infection was 
further emphasised in the RV144 vaccine trial, where an estimated 30% of vaccinated individuals 
were protected from acquiring HIV. Detailed analysis revealed that the protective effect correlated 
with induction of IgG3 responses and high ADCC activity of the elicited antibodies (Chung et al., 
2014). 
 One of the first broadly-neutralising HIV antibodies discovered using next generation 
methods, VRC01 (Wu et al., 2010), has rapidly become an important clinical candidate for HIV 
prevention and treatment (Ledgerwood et al., 2015). A single injection of VRC01 antibody provided 
8-week protection against HIV infection in macaques, which was extended to 14.5 weeks by 
improving its binding to FcRn (Gautam et al., 2016). Moreover, an engineered VRC01 demonstrated 
increased FcRn-mediated delivery to gut mucosal tissue resulting in enhanced mucosal localisation 
and improved protection against SHIV challenge (Ko et al., 2014). In humans, VRC01 has been the 
subject of numerous completed and current clinical trials (Bar et al., 2016; Crowell et al., 2019; 
Riddler et al., 2018), which all demonstrate that the antibody is safe and well-tolerated. Whilst 
protective efficacy has not been prominent, it is widely agreed that monoclonal antibody 
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monotherapy is insufficient and that combination therapy with at least two mAbs is a minimum 
requirement (Mendoza et al., 2018). 
Plants are becoming established as a “low-tech”, cost-effective and scalable production 
system for biopharmaceuticals including monoclonal antibodies (mAbs) (Paul et al., 2013). Molecular 
Pharming is particularly attractive in the field of HIV antibody therapeutics as the major limitation of 
antibody-based anti-HIV agents remains their high cost of manufacturing(Ma et al., 2013). Recently, 
the first GMP manufacturing license for plant mAbs was awarded in Europe, which led to a first-in-
man phase I clinical trial (Ma et al., 2015b). The only significant difference between mAbs produced 
in plant and mammalian cells results from different glycosylation pathways leading to production of 
antibodies with different glycan composition. Plant glycoproteins are characterised by core α1,3-
fucose and β1,2-xylose resides, and lack of galactose and sialic acid residues(Bosch et al., 2013), 
which was shown to have a negative impact on ADCVI (antibody-dependent cell-mediated virus 
inhibition) activity against HIV of some (Forthal et al., 2010), but not all  (Rosenberg et al., 2013) 
plant-produced antibodies. 
mAb VRC01expressed in plants demonstrated similar antigen binding and HIV neutralization 
activity to VRC01 produced in HEK cells (Rosenberg et al., 2013; Teh et al., 2014). However, plant-
derived VRC01 was cleared rapidly from the bloodstream in macaques (Rosenberg et al., 2013). The 
reason for the rapid clearance observed for some plant-made antibodies is unknown and results are 
inconsistent (Khoudi et al., 1999; Lee et al., 2013; Triguero et al., 2011). It has been suggested that 
distinct glycosylation of recombinant antibodies expressed in non-human systems might have an 
indirect effect on FcRn binding (Jefferis, 2009a), even though human glycosylation does not affect 
binding of IgG to FcRn directly, because the receptor does not come in close contact with the Fc 
glycans (Martin et al., 2001; Nezlin and Ghetie, 2004).  
In this study, the primary objective was to perform a comprehensive analysis of the impact 
of glycosylation on mAb VRC01 interactions with Fc receptors. Also, other post-translational 
modifications, like methionine oxidation were assessed in context of FcRn binding. A panel of 
engineered glycovariants of VRC01 were generated in N. benthamiana and Fc gamma receptor 
binding was characterised by kinetics and affinity measurement as well as effector function. The 
plant-derived antibodies were evaluated for interactions with FcRn. 
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Results 
 
VRC01 antibody glycovariants produced in N. benthamiana.  
cDNA sequences encoding antibody heavy and light chain were cloned into a binary vector 
(Sainsbury et al., 2009) and transiently expressed in N. benthamiana using agroinfiltration (Kapila et 
al., 1997). Purified antibodies were subjected to glycan analysis by liquid chromatography-
electrospray ionization-mass spectrometry (LC-ESI-MS) to identify and quantify N-glycan populations 
in the Fc region. Each glycovariant was produced in 2-3 batches and successful glycoengineering of 
extra batches was confirmed by immunoblotting (data not shown). Mass spectra of tryptic 
glycopeptides revealed that the main structure on VRC01 expressed transiently in WT 
N. benthamiana (VRC01WT) is a typical plant glycan with β1,2-xylose- and core α1,3-fucose residues 
(GnGnXF3), accounting for 54.1% of the entire population (Table 1, Supplementary Figure S1). A high 
proportion of VRC01WT heavy chains (36%) appeared to be unglycosylated, and there were also 
minor populations of incompletely processed glycans. VRC01 expressed in the ΔXT/FT plant line 
(VRC01ΔXF), where β1,2-xylosylation and core α1,3-fucosylation had been silenced (Strasser et al., 
2008), demonstrated a homogenous glycosylation pattern with a dominant structure GnGn (74.6%). 
No xylosylated or fucosylated glycan structures were detected, and in this case, 21.2% of the heavy 
chains were unglycosylated. To further modify the plant N-glycans by addition of terminalβ1,4-
galactose, VRC01 was co-expressed with a human β1,4-galactosyltransferase targeted to the late 
Golgi compartment, in the ΔXT/FT plant line (VRC01Gal). This resulted in heterogeneous glycosylation 
of the heavy chains, with several structures (approx. 50%) carrying at least one galactose residue. As 
in VRC01∆XF, no xylose and fucose residues could be detected in the VRC01Gal heavy chain. Almost 
30% of VRC01Galheavy chains were unglycosylated. 
The glycosylation profile of VRC01 antibody derived from HEK cells, was also analysed (VRC01HEK), 
revealing a heterogeneous pattern with the most prevalent structure being GnGnF6 (70.5%). 
Galactosylated structures, but not sialylated, were also present. 3.1% of the heavy chains were 
unglycosylated. Finally, a plant-produced VRC01 variant lacking Fc N-glycans was created by site-
directed mutagenesis (VRC01aglyco). Disruption of the N-glycosylation site by N297S mutation was 
verified through DNA sequencing and the absence of N-glycans on the heavy and light chains was 
further indicated at the protein level by SDS-PAGE of antibodies analysed under reducing conditions 
(data not shown). 
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Binding kinetics and affinity of VRC01 to FcγRI and FcγRIIIa. 
Binding kinetics and affinities of mAb Fc interactions with FcγRs were performed using surface 
plasmon resonance. Each VRC01 glycovariant was individually captured onto a protein A‐coated 
sensor chip and recombinant human FcγRI ectodomains were injected over the antibody surface at a 
range of concentrations. Sensorgrams were analysed with a 1:1 binding model except for VRC01WT 
where a modified version of the heterogeneous ligand binding model was used to fit the biphasic 
binding behaviour of the unglycosylated and glycosylated mix in VRC01WT (Figure 1A). The model was 
created by incorporating kinetic parameters for unglycosylated VRC01 to the heterogeneous binding 
model to cover the unglycosylated portion of VRC01WT and thus to extract kinetics for the 
glycosylated portion of VRC01WT.VRC01Gal was also tested with both this heterogeneous binding 
model that assumes an aglycosylated portion of VRC01 and the standard 1:1 binding model 
(Supplementary Figure S2).  The same kinetics for galactosylated VRC01 were obtained regardless of 
the model choice– the aglycosylated portion of VRC01Gal was recognised and discarded by the 1:1 
binding model as artefact. Accordingly, the simplest model (usually 1:1 binding kinetics) was always 
chosen. Chi2 values were assessed for all kinetics analysis, and data is only reported when deviation 
of the fit was <5% Rmax. 
VRC01HEKhad the highest affinity to FcγRI with a dissociation constant (KD) of 98pM, VRC01ΔXF and 
VRC01Gal had KDs of 247pM and 558pM respectively (Figure 3). VRC01WT formed significantly less 
stable complexes with the receptor (KD = 3 nM) and removing Fc glycosylation reduced affinity to 
FcγRI by another order of magnitude (71 nM, VRC01aglyco) and caused immediate dissociation of the 
antibody-receptor complex (Figure 1A).Kinetic analysis revealed that changes in glycosylation mainly 
affected the dissociation rate constant, without influencing the association rate constant 
significantly (Figure 1B). As a consequence, glycosylation altered stability of antibody – FcγRI 
complexes, reducing their half-life from about 1h to 5 min for typical plant N-glycans, and to only 
seconds for unglycosylated antibodies (Figure 1C). 
To study binding to FcγRIIIa, a polymorphic variant with high affinity to IgG1, FcγRIIIa-V158(Ravetch 
and Perussia, 1989), was selected. Previous studies demonstrated that the interaction does not 
follow the 1:1 binding model despite 1:1 stoichiometry (Frostell, 2012; Frostell, 2015), probably due 
to conformational change that may occur during the binding event (Hayes et al., 2014). Three-
dimensional structures of the FcγRIIIa-Fc complex suggest that the receptor makes close contact 
with one arm of the heavy chain first and then locks its position in between the two chains (Ferrara 
et al., 2011). For these reasons, the binding sensorgrams were analysed using the two-state reaction 
interaction model. These revealed that VRC01HEK binds FcγRIIIa with rapid on and off rates (Figure 
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1A). The affinity was 620 nM (Figure 3). In contrast, VRC01ΔXF and VRC01Gal, formed more stable 
complexes, primarily through slower off rates, resulting in approximately one order of magnitude 
higher affinity (32.6 nM and 59 nM, respectively). Additionally, for VRC01Gal a 28% reduction in 
saturation level (Rmax) was observed, indicating that a proportion of molecules is inactive for 
FcγRIIIa binding. This correlated with 29.4% aglycosylation in VRC01Galsample that was detected by 
LC-ESI-MS (Table 1). Indeed, when N-glycans were absent, the unglycosylated antibodies 
(VRC01aglyco) could not engage the receptor at any of the tested concentrations (Figure 1C). VRC01WT 
exhibited an interesting binding pattern to FcγRIIIa, which is characterised by two aspects. Firstly, 
the binding responses saturated at 20% of the expected level indicating that about 80% of the 
VRC01WT molecules cannot engage FcγRIIIa at all. Secondly, the remaining 20% of VRC01WT 
antibodies had a slightly higher affinity to FcγRIIIa than VRC01HEK, estimated to be 430 nM.  
 
Affinity to FcγRIIa and FcγRIIb. 
Implications of antibody glycovariants were also analysed for two low-affinity FcγR receptors, FcγRIIa 
and FcγRIIb. For this study, the more prevalent polymorphic variant of FcγRIIa (R131) was selected 
(Osborne et al., 1994; Warmerdam et al., 1990). 
Steady-state affinity measurements revealed that VRC01HEK binds FcγRIIa with an affinity of 937 nM 
(Figure 2; Steady state graph data are shown in Supplementary Figure 3). Binding of the plant-
produced VRC01WT was too low to measure under the assay conditions, but the affinity of the 
interaction appears to be lower than 7 μM. Engineering Fc glycosylation restored binding of plant-
made antibodies to FcγRIIa, as demonstrated by VRC01ΔXFand VRC01Gal (affinities 780 nM and 1.5 
μM, respectively). As with FcγRIIIa, the VRC01Galpreparation appears to contain approximately29% 
inactive molecules, as indicated by a mismatch between the experimental and theoretical Rmax. This 
observation correlates with the extent of aglycosylation measured by mass spectrometry (Table 1). 
Interaction of the VRC01 glycovariants with FcγRIIb exhibited a similar binding pattern as for FcγRIIa. 
Plant-made VRC01WT had an affinity lower than 7 μM, which was improved in the glycoengineered 
variants VRC01ΔXF and VRC01Gal (2.5 μM and 3.7 μM, respectively), reaching a similar level to 
VRC01HEK (3.4 μM) (Figure 2; Steady state graph data are shown in Supplementary Figure 4).  
VRC01aglyco did not bind FcγRIIa and FcγRIIb at any concentration tested, indicating that 
unglycosylated antibodies are not able to engage these receptors. 
The relative affinities for all antibodies against Fc receptors, measured by SPR, are summarised in 
Figure 3. 
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Binding to cell surface FcγRs. 
 Binding of VRC01 glycovariants to FcγRs was further analysed in a cellular context, using 
THP-1 monocytes(Tsuchiya et al., 1980). Flow cytometric analysis demonstrated that these cells 
express FcγRI and FcγRII receptors on the surface, but no FcγRIII could be observed (Figure 4A). The 
cells were incubated with VRC01 antibodies and binding was detected with specific antibody 
fragments conjugated to FITC fluorochrome. All antibodies except VRC01aglycodemonstrated binding 
to the cells (Figure 4B). However, VRC01WTdid not engage the cell surface FcγRs as effectively as 
VRC01HEK. Engineering plant glycosylation improved binding of the plant-made antibodies to cells 
(VRC01ΔXF and VRC01Gal). The observations are consistent with the binding results obtained in the 
SPR-based assays. 
To demonstrate a functional impact of increasing binding affinity to FcγRIIIa, an ADCC reporter 
bioassay was used (Figure 4c). Dilutions of VRC01WT, VRC01ΔXF and VRC01HEKwere pre-incubated with 
HIV-1 gp140, before incubating with engineered Jurkat effector cells (ADCC Bioassay Effector cells). 
In this assay, FcγRIIIa activation is directly proportional to the luciferase activity in the effector cells. 
FcγRIIIa activation induced by VRC01WTand VRC01HEK was similar. However, FcRγIIIa activation by 
VRC01ΔXF was approximately 25-fold higher. This is consistent with the results of the FcγRIIIa analysis 
described above as well as other studies (Forthal et al., 2010; Junttila et al., 2010; Zeitlin et al., 
2011). Luciferase activity of control samples with no antibody (gp140+cells only) or no gp140 (mAb + 
cells only) were not significantly different to PBS (data not shown).  
 
Binding to FcRn. 
FcRn is an important receptor that can influence and modulate the course of antibody-based 
therapy. Although the exact binding mechanism in vivo is still unclear, recent studies provide strong 
evidence that each IgG heavy chain can bind one FcRn molecule independently with identical affinity 
(Abdiche et al., 2015; Oganesyan et al., 2014). The resulting 2:1 FcRn-IgG complex is then 
characterised by stronger interaction due to avidity (Tesar et al., 2006).  
SPR analysis was performed in two assay orientations. FcRn were either immobilised on the 
sensor chip surface allowing antibodies to slot between two receptors, resulting in strong avidity 
interaction, or they were injected in solution over an antibody-coated surface allowing for 
independent interaction with each antibody arm. Due to the pH-dependent nature of the 
interaction, where antibodies engage the receptor in acidic conditions of the endosome and are 
released at physiological pH of the blood (Vaughn and Bjorkman, 1998), the binding in this assay was 
measured at pH 6.0.In the first strategy, different VRC01 glycovariants were injected at 200 nM in 
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duplicate (Figure 5A). The sensorgrams show that VRC01HEK generates the highest binding responses, 
indicating higher affinity, followed by all plant-produced variants, which have comparable binding 
levels, including unglycosylated VRC01. Formation of stable multivalent complexes was observed, as 
characterised by very slow dissociation curves.  All the complexes dissociated efficiently at 
physiological pH 7.4. In the second, avidity-free assay orientation, soluble monomeric FcRn was 
injected at 200nM in duplicate (Figure 5B). Again, VRC01HEK generated the highest binding responses 
and FcRn bound all the plant-produced variants similarly, to a level of around 2/3 of VRC01HEK. The 
observed difference suggests a higher affinity of VRC01HEK to FcRn, however the presence of partially 
degraded antibodies in plant samples is commonly found (Hehle et al., 2011)and could also cause a 
decrease in observed binding levels. Therefore, affinity values for all VRC01 glycovariants to 
recombinant human FcRn were measured in a steady-state affinity assay. Briefly, each antibody was 
captured to the same level onto an anti-human Fab surface, followed by injection of FcRn at a range 
of concentrations (Supporting information Figure S5).The steady-state affinity measurements 
revealed that all glycoforms have a fairly similar affinity to FcRn, with VRC01HEK exhibiting slightly 
higher affinity (199nM) than the plant-produced variants (272–310nM). The difference is unlikely to 
result from different plant glycosylation, given that neither glycoengineering (VRC01ΔXF and VRC01Gal) 
nor removing the Fc glycan (VRC01aglyco) affected antibody affinity to the receptor significantly. 
Another possibility might be antibody oxidation, which has been previously reported to reduce 
antibody affinity to FcRn (Bertolotti-Ciarlet et al., 2009; Pan et al., 2009), and this was investigated in 
the next experiment. 
Methionine oxidation. 
It was previously observed that oxidation of two methionine residues, Met252 and Met428, on the 
antibody heavy chain can result in up to 10-fold reduced affinity to FcRn (Bertolotti-Ciarlet et al., 
2009; Gao et al., 2015). The plant-made VRC01 samples, together with a new VRC01HEK batch, were 
therefore analysed to measure percentage oxidation of these two methionine residues. 
Heavy chains were separated by gel electrophoresis and enzymatically digested to corresponding 
peptides containing Met252 or Met428 residues: DTLM252ISR and SCSVM428HEALHNHY. The relative 
percentage oxidation was calculated from MS spectra, by comparing a proportion of the peak 
heights corresponding to an oxidised versusnon-oxidised peptide containing either the Met252 or 
Met428 residues. The sequence identity of oxidised and non-oxidised peptides (both DTLM252ISR and 
SCSVM428HEALHNHY), as well as formation of methionine sulfoxide (MetOx), was further confirmed 
by MS-MS (data not shown). 
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Mass spectrometry analysis of methionine oxidation revealed that all the plant-produced VRC01 
antibodies contained significantly more methionine sulfoxide in the Met252 position (50-70%) as 
compared to VRC01HEK (20%) (Figure 6). Met428 displayed a different oxidation pattern than 
Met252, with VRC01HEK and all plant antibody glycovariants having similar oxidation levels 50-76%.  
Four separate batches of VRC01WT were subsequently produced to investigate the possibility of 
controlling Met252 and Met428 oxidation during plant antibody extraction, purification and storage. 
The batches of VRC01WT were prepared, with and without the addition of an anti-oxidant during 
antibody extraction, and stored under nitrogen gas or not. Mass spectrometry analysis of 
methionine oxidation was performed as above. There was no significant difference in Met252 or 
Met428 oxidation between any of the downstream processing strategies (data not shown), 
suggesting that methionine oxidation is likely to take place in planta, rather than during antibody 
extraction and storage.   
 
Discussion 
Four activating receptors, FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and one inhibitory receptor FcγRIIb 
(Ravetch, 2010) are differentially distributed on immune cells. They can be found on all leukocytes 
and platelets except T cells(Guilliams et al., 2014; Hogarth and Pietersz, 2012) and many cells have 
multiple FcγRs on their surface. Once bound to antigen, antibodies can mediate a range of immune 
functions through interaction with FcγR. Engagement of activating FcγRs can induce i) antibody-
dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis 
(ADCP), which both result in direct killing of antibody-opsonised cells, ii) release of pro-inflammatory 
mediators and cytokines, to attract other white blood cells to the infection site and activate them, as 
well as iii) antigen endocytosis and presentation, to further enhance the immune response 
(reviewed in (Desjarlais and Lazar, 2011)).  
In order to study the effect of plant N-glycosylation on recombinant antibody Fc-mediated binding 
activities, the broadly-neutralising HIV antibody, VRC01, was expressed in plants in different glycol 
formats. Our studies revealed that VRC01 with typical plant glycosylation had 30-fold lower affinity 
to recombinant human FcγRI than the same antibody produced in HEK cells. Also, it had a limited 
ability to bind the low affinity receptors FcγRIIa, FcγRIIb and FcγRIIIa. Removal of Fc glycans by 
mutagenesis of Asn297 resulted in a complete loss of binding.  However, engineering plant glycans 
by removal of core fucose and xylose significantly improved affinity of plant-made VRC01 to FcγRI 
and restored binding activity to FcγRIIa and FcγRIIb. Moreover, affinity of fucose/xylose-free 
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antibodies to FcγRIIIa was 10 to 20-times enhanced as compared to the HEK cell-derived VRC01. The 
impact of fucose removal on binding to FcγRIIIa was previously observed for antibodies generated in 
mammalian cell and plant-based systems (Cox et al., 2006; Shields et al., 2002) and likely results 
from steric interference with glycans present in the binding site of FcγRIIIa (Ferrara et al., 2011). 
Extending the fucose- and xylose-free antibodies with terminal β1,4-galacose residues did not 
further improve their interaction with Fc gamma receptors. Cell-based binding assays with THP-1 
monocytes confirmed the binding behaviour of different VRC01 glycovariants observed in the SPR 
analysis.  
The binding of VRC01WT to FcγRIIIa indicated that about 80% of antibody molecules did not 
engage the receptor. The remaining active proportion had an affinity of 430 nM, as compared to 620 
nM for VRC01HEK. The inactive proportion correlates with the proportion of molecules either with no 
Fc glycans or containing typical plant GnGnXF3 structures. This suggests that not only unglycosylated 
antibodies, but also GnGnXF3 glycoforms might not be able to bind FcγRIIIa. The core fucose in plants 
is α1,3-linked, rather than the α1,6-link in mammalian systems, but the results suggest the 
differentially oriented fucose on plant-produced antibodies still causes steric constraints in the 
FcγRIIIa binding site, abrogating the interaction. The active portion of VRC01WT antibodies, that 
engages FcγRIIIa more effectively than VRC01HEK, might correspond to the non-fully processed 
glycoformsthat were found in the sample.  These comprise oligomannose structures lacking core 
fucose and truncated complex glycans containing fucose. Thus, VRC01WT antibody produced in plants 
appears to be a mixture of FcγRIIIanon-binders and binders with different affinities, depending on 
the glycoform they carry. This variability may translate functionally into potentially different ADCC 
activities. 
Non-glycosylation had a significant effect on antibody receptor-binding. Glycopeptide analysis 
revealed that all VRC01 antibody preparations contained a proportion of unglycosylated heavy 
chains. This was very low in the HEK-derived VRC01 (<5%), but reached higher levels when the 
antibody was expressed in N. benthamiana (21-35% depending on the glycoengineering strategy). 
Recombinant glycoproteins generated in plant systems are often fully glycosylated, however some 
studies have previously reported partial aglycosylation of plant-made antibodies (Jez et al., 2012; 
Schuster et al., 2007; Teh et al., 2014; Zeitlin et al., 2011). The reason for hypoglycosylation of some 
plant-made antibodies is unknown, but seems to be antibody specific. A powerful strategy for 
enhancing glycosylation efficiency is the over/co-expression of the oligosaccharyltransferase 
complex (OST), which is the central-protein complex facilitating the N-glycosylation of proteins in the 
lumen of the endoplasmic reticulum(Castilho et al., 2018).  
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Serum antibodies naturally demonstrate a high level of glycan heterogeneity, exhibiting as 
many as 30-40 different glycoforms (Nimmerjahn and Ravetch, 2008; Stadlmann et al., 2008). The 
functional relevance of such glycan heterogeneity is not fully understood, however the glycoform 
profile may be skewed in pathology or in response to pathogens (Ackerman et al., 2013; Jefferis, 
2012). This indicates that glycan heterogeneity might be important and antibodies with 
heterogeneous glycoprofile might actually be preferred over those with a single glycoform. 
However, a better understanding of the role of individual glycan residues is needed first, before we 
can start to consider how best to mimic a natural antibody response. 
At present, therapeutic monoclonal antibodies are generally obtained from mammalian cell-
based production systems which usually generate a mixture of about 5-9 different glycoforms 
(Stadlmann et al., 2008). Given that individual glycoforms may have different functional activities, 
such a mixture may potentially contain antibody molecules with limited or no activity. In future, 
control of the glycosylation profile of monoclonal antibodies for therapeutic use may therefore need 
to be considered more carefully. An ultimate goal might be to develop a reproducible optimised mix 
of glycoforms for a specific application. 
Attempts to isolate a single glycoform from a heterogeneous mixture of glycovariants by 
affinity chromatography have met with limited success(Bolton et al., 2013) and purification of a 
single glycoform is currently not feasible(Loos and Steinkellner, 2012). Several approaches have 
been undertaken to reduce antibody glycosylation heterogeneity, including use of glycan-modifying 
enzymes in vitro (Thomann et al., 2015) and genetic modification (Piron et al., 2015). Plants offer an 
attractive solution for producing highly homogeneous antibodies and other proteins with defined 
glycosylation(Madeira et al., 2016; Montero-Morales and Steinkellner, 2018). Although expression of 
antibodies in WT plants can yield a proportion of non-fully processed glycans, glycoengineered plant 
lines usually produce highly homogeneous glycoforms (Ma et al., 2015a; Strasser et al., 2009; 
Strasser et al., 2008). Here, VRC01 antibody generated in ΔXF N. benthamiana contained a single 
predominant glycoform, GnGn, accompanied by MGn (4.7%). Although LC-ESI-MS analysis suggested 
the presence of 20% of unglycosylated heavy chains, this could not be confirmed in Western blot or 
SPR analyses. Typically, inactivation of endogenous glycosyltransferases in plants results in over 80% 
purity of GnGn glycoforms(Castilho et al., 2015; Strasser et al., 2008). Galacosylated VRC01Gal 
produced in this study by transient co-expression of human galactosyltrasferase was characterised 
by high heterogeneity, however a recently developed plant transgenic platform is able to produce 
antibodies lacking core fucose and xylose where 90% of molecules carries galactosylated N-glycans, 
including 60% of bi-galactosylated structures (AA) (Schneider et al., 2015).  
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 Antibody binding to neonatal Fc receptor is reported to be independent of Fc glycosylation 
(Nezlin and Ghetie, 2004), as FcRn engages residues present on the CH2–CH3 domain interface 
(Burmeister et al., 1994; Oganesyan et al., 2014). but a concern was raised that unusual glycan 
structures from non-mammalian protein expression systems may affect the binding 
indirectly(Jefferis, 2009a). Our SPR analysis confirmed that plant N-glycosylation did not have an 
adverse effect on binding to FcRn. All plant VRC01 glycovariants had similar affinity to FcRn,that was 
slightly lower than VRC01 from HEK cells. However, binding reduction correlated with increased 
oxidation levels of a methionine residue (Met252) present in the Fc region, which has previously 
been reported to have a negative impact on the IgG-FcRn interaction(Gao et al., 2015). 
 Protein oxidation in recombinant protein production is an important factor influencing 
stability and functionality of protein pharmaceuticals(Li et al., 1995; Pan et al., 2009). Susceptible 
amino acids, like His, Met, Cys, Tyr and Trp can be oxidised by a number of factors at any stage of the 
production, extraction, purification and storage(Manning et al., 2010). Methionine residues are 
particularly sensitive to reactive oxygen species and can oxidise to methionine sulfoxide even in the 
presence of molecular oxygen. Different methionine residues can oxidise at different speeds, with 
surface-exposed residues oxidising faster, whereas those buried in a protein backbone oxidise more 
slowly(Griffiths and Cooney, 2002). 
 Extraction of recombinant proteins from plant tissues presents many challenges. Plant 
leaves are rich in polyphenols(Li et al., 2003), which in response to tissue damage and exposure to 
air are enzymatically oxidised to reactive semiquinone radicals and quinones, which further attack 
sensitive residues on proteins (Met, Cys, Trp) (Synge, 1975). Polyphenol oxidation can also occur 
during protein extraction from plants(Hurrell et al., 1982). It has also been reported that during 
extraction, methionine sulfoxide is formed(Pirie, 1975). Protection of recombinant proteins from 
oxidation during plant extraction has not been widely studied, however general preventive 
procedures have been used e.g. thiosulfate, citrate (Chargelegue et al., 2005), ascorbic acid or 
Gamborg’s B5 vitamin solution (Miletic et al., 2015). Reducing polyphenol oxidation can be 
attempted by addition of chelating agents like EDTA, and sometimes sucrose is also included, to limit 
solvent accessibility (Miletic et al., 2015). In our study, oxidation of Met252 and Met 458 was 
unaffected by antioxidant in the antibody extraction buffer, or storage in non-oxidising conditions 
after extraction. Although further studies are required, this suggests that antibody oxidation may 
occur at an earlier stage in antibody expression, pointing to the likelihood that antibody mutagenesis 
strategies(Dall'Acqua et al., 2002; Zalevsky et al., 2010)might prove more useful. 
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In conclusion, this is a comprehensive report of the impact of two post-translational 
modifications affecting antibodies produced in plants, on their Fc effector functions. We 
demonstrated the importance of glycosylation for binding to high and low affinity Fc receptors and 
the potential role of glycoengineering strategies in plants to produce antibodies with potent 
opsonisation and ADCC activity. We extended our studies to formally demonstrate that plant 
glycosylation does not significantly affect binding of antibodies to FcRn receptor, but that oxidation 
of at least one methionine residue in the Fc region has an impact on FcRn affinity. Our results 
suggest that the reported accelerated clearance of some plant-produced antibodies from the 
bloodstream (Ko et al., 2003; Rosenberg et al., 2015; Triguero et al., 2011)might be attributable to 
this and other clearing mechanisms.  
 
Materials and Methods 
VRC01HEK was obtained from the Centre for AIDS Reagents, UK. 
Site-directed mutagenesis and gene cloning. 
VRC01 heavy and light chain gene sequences were plant-codon optimised for tobacco (provided by 
Mapp Biopharmaceutical, Inc). The heavy chain sequences were mutagenised using the 
QuickChange® (Stratagene) protocol and primers designed to replace the Asn codon with Ser at 
position 297. Transformed colonies were selected and plasmids were isolated using QIAprep® Spin 
Miniprep Kit (Qiagen) and confirmed by sequencing. Both mutated and original sequences of VRC01 
light and heavy chain were sub-cloned into the plant expression vector pEAQ-HT-DEST3 (Sainsbury et 
al., 2009)by LR recombination using the Gateway cloning system (Invitrogen). DH5α competent E. 
coli cells were transformed and colonies containing pEAQ-HT vectors with appropriate gene 
constructs were selected using kanamycin. Expression vectors were isolated by QIAprep® Spin 
Miniprep Kit (Qiagen). 
Antibody expression in N. benthamiana and purification. 
Expression vectors pEAQ-HT-DEST3 containing heavy and light genes were introduced into two 
different Agrobacterium tumefaciens strains: GV3101:pMP90 was used for the heavy chain 
constructs and LBA4404 for the light chain construct. Agrobacteria were grown overnight at 28°C in 
YENB medium with 50 μg/ml rifampicin and appropriate antibiotics to select for helper plasmid and 
expression vector. For infiltration, bacteria were resuspended in 0.1 mM acetosyringone (Santa Cruz 
Biotechnology, USA), 0.01 mM MES (Sigma, USA) and 0.01 mM MgCl2 (VWR International, UK) to a 
final OD600 of 0.2. Vacuum infiltration of N. benthamiana leaves was performed as previously 
described(Kapila et al., 1997), using 4-week-old plants and applying vacuum for 1 min at 100 mbar. 
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To produce glycoengineered VRC01 antibodies (VRC01ΔXF), the N. benthamiana ΔXF plant 
line(Strasser et al., 2008) was used for agroinfiltration. To generate the galactosylated glycovariant 
(VRC01Gal), the ΔXF N. benthamiana plants were additionally co-infiltrated with agrobacteria 
containing pST plasmid with human β1,4-galactosyltransferase (GalT) (Strasser et al., 2009). Vacuum 
infiltrated leaves were harvested at 6 days post-infection. Antibodies were extracted in 100 mM Tris 
buffer pH 8.0, 150 mM NaCl and purified using a Protein A-Agarose (Sigma, USA) column, eluting 
antibodies with 0.1 M glycine-HCl pH 2.7 into 1M Tris-HCl pH 9.0 neutralising buffer. Purified 
samples were dialysed into PBS with Slide-A-Lyzer Cassettes (molecular cut-off 3.5 kDa; Thermo 
scientific, USA) and stored under nitrogen in glass HPLC tubes with septum (10mm PP Screw Cap, 
Fisher Scientific).  
For cell assays, the concentration of full-size antibodies was calculated using densitometry analysis 
of identified IgG band on Coomassie stained SDS-PAGE gels. Standard curves for known 
concentrations of bovine serum albumin and another plant derived IgG antibody (P2G12) were 
generated using the BCA Protein assay and VRC01 concentration values were interpolated from 
nonlinear regression fit using second order polynomial (quadratic) equation.    
In the experiment to control antibody oxidation during processing and storage, VRC01WT was 
expressed in the same way except that antibodies were extracted using PBS (pH 7.4) with or without 
10 mM sodium metabisulfite. 
 
LC-ESI-MS confirmation of glycoengineering. 
Following separation by SDS-PAGE under reducing conditions, heavy chain bands were excised, S-
alkylated with iodoacetamide and digested with sequencing grade modified trypsin (Promega). 
Fragments were eluted from the gel with 50% (vol/vol) acetonitrile and loaded on a BioBasic C18 
column (BioBasic-18, 150 x 0.32 mm, 5 µm, Thermo Scientific) using 65 mM ammonium formiate 
buffer as the aqueous solvent. A gradient from 5% B (B: 100% acetonitrile) to 32% B in 45 min was 
applied at a flow rate of 6 µL/min, followed by a 15 min gradient from 32% B to 75% B that facilitates 
elution of large peptides. Detection was performed with a QTOF MS (Bruker maXis 4G) equipped 
with the standard ESI source in positive ion, data dependent mode (= switching to MSMS mode for 
eluting peaks). MS-scans were recorded (range: 300-2000 Da) and the 6 highest peaks were selected 
for fragmentation. Instrument calibration was performed using an ESI calibration mixture (Agilent). 
Results were evaluated using Data Analysis 4.0 (Bruker). Co-eluting glycopeptide peaks were 
identified by their exact mass. 
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FcγR binding kinetics and affinity measurements. 
SPR assays were performed using a Biacore™ X100 instrument (GE Healthcare). First, a protein A 
sensor chip was prepared by immobilizing recombinant protein A (Sigma) in both flow cells of a CM5 
sensor chip to 5000 RU using the Amine Coupling Kit (GE Healthcare). VRC01 samples were diluted in 
HBS-EP+ buffer and captured onto the Protein A surface (flow cell 2) to the levels around 240RU (for 
FcγRI analysis) or 330RU (for FcγRIIIa) or 680RU (for FcγRIIa and FcγRIIb).  Recombinant human FcγR 
ectodomains (R&D) were injected over both flow cells at 25°C for 135s at 40 µl/min (FcγRI), 40s at 50 
µl/min (FcγRIIIa when tested against fucosylated antibodies), 90s at 40 µl/min (FcγRIIIa when tested 
against afucosylated antibodies) or 30s at 45 µl/min (FcγRIIa and b). The FcγR-VRC01 complexes 
were removed with two 90 s injections of 10 mM glycine-HCl pH 1.5. If the regeneration was not 
fully successful the first injection was replaced with 10 mM glycine-HCl 3.5M MgCl2 pH 1.5 buffer. 
Receptors were analysed at following concentrations: FcγRI – 2-240 nM (480 nM for VRC01aglyco); 
FcγRIIIa –  0.125-4 μM (12-800 nM for afucosylated antibodies VRC01ΔXF and VRC01Gal); FcγRIIa and 
FcγRIIb – 0.5-8 μM. Half-life of antibody-receptor complexes was calculated from dissociation rate 
constants according to the formula: T1/2 = ln2/koff. 
Surface expression of FcγRs on THP-1 cells. 
The THP-1 cell line (ATCC) was grown in RPMI culture medium at 37°C and 5% CO2 atmosphere. The 
cells were harvested by centrifugation (300 RCF, 5 min) and concentrated to 2x106 cells/ml in PBS 
with 2.5% BSA and 0.1% sodium azide (FACS buffer). To determine FcγRI expression the cells were 
incubated with 10 µg/mL mouse anti-human FcγRI antiserum (R&D) for 1 h on ice. Mouse IgG1 
(Sigma) was used as an isotype control. The cells were washed twice with the FACS buffer by 
centrifugation at 300 RCF for 5 min and incubated with 1:100 FITC-conjugated anti-mouse 
immunoglobulins antibody (The Binding Site). For FcγRII and FcγRIII expression the cells were 
incubated with 0.25 µg/test of FcγRII-FITC or FcγRIII-FITC antibody (eBioscience) for 1 h on ice. 
Mouse IgG1-FITC (BD Biosciences) was used as an isotype control. The cells were washed twice and 
fluorescence intensity was measured by BD FACSCanto™ II Flow Cytometer (BD BioSciences) using 
BD FACSDiva™ Software. The data were analysed using FlowJo V10.1 software. 
VRC01 binding to cell receptors.   
THP-1 cells were harvested by centrifugation (300 RCF, 5 min) and concentrated to 5x106 cells/ml in 
FACS buffer. The cells were incubated with serially diluted VRC01 samples for 1 h on ice and excess 
antibodies were washed off twice with FACS buffer by centrifugation at 300 RCF for 5 min. Binding of 
VRC01 samples to THP-1 cells was detected with 1:200 FITC-conjugated F(ab’)2 fragment against 
human Ig light and heavy chains (Jackson ImmunoResearch Laboratories, Inc.) by 20 min incubation 
on ice. The cells were washed twice and fluorescent intensity was measured by BD FACSCanto™ II 
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Flow Cytometer (BD BioSciences). Mean fluorescent intensity (MFI) values were derived by 
subtracting MFI of THP-1 cell populations treated with the F(ab’)2 fragment only. Binding curves 
were created using non-linear curve fit (One site - Specific binding) with GraphPad Prism 6 software. 
FcγRIIIa activation reporter assay. 
The ADCC Reporter Bioassay was performed according to manufacturer’s protocol (Promega, USA), 
using soluble HIV-1 UG37 gp140 (CFAR, UK) instead of target cells. 0.08, 0.4, 2 and 10µg/ml antibody 
was pre-incubated with free HIV-1 gp140 (5µg/ml) for one hour. ADCC Bioassay Effector cells (Jurkat 
cells stably expressing the high affinity (V158) FcγRIIIa receptor and an NFAT response element 
driving expression of firefly luciferase) were added at 1.5x105 cells/well and the assay plates were 
incubated at 37oC, 5% CO2 for 24 hours. Bio-Glo
TM luciferase assay reagent was added and 
luminescence measured in a GloMax 96 plate reader (Promega, USA). In this assay, luciferase activity 
in the effector cells is directly proportional to FcγRIIIa activation. 
FcRn binding analysis. 
For binding analysis two strategies were employed. Firstly, recombinant human FcRn ectodomain 
(SinoBiological Inc.) was diluted in 10 mM acetate buffer pH 4.5 and immobilized on the CM5 sensor 
chip surface to 1000 RU by amine-coupling (Amine Coupling Kit, GE Healthcare). Reference surface 
was ‘blank immobilised’ by activation with NHS/EDC and blocking with 1 M ethanolamine-HCl pH 
8.5. Binding analysis was performed in PBS-P+ buffer (PBS 0.05% Tween20) pH 6.0.To minimise 
differences in pH between different samples VRC01 antibodies were pre-diluted to 1200 nM in PBS 
pH 7.4 and then injected at 100 nM in PBS-P+ pH 6.0 for 120 s contact time and 120 s dissociation 
time at a flow rate 40 μl/min. Samples were run in duplicate and the surface was regenerated with a 
60s injection of PBS pH 7.4. 
In the second strategy, anti-human Fab antibodies (Fab Capture Kit) were diluted to 20 μg/ml in 
10 mM acetate buffer pH 5.0 and immobilized on a CM5 sensor chip to 6000 RU in both flow cells, by 
amine coupling.  VRC01 antibodies were then captured in flow cell 2 only. Recombinant human FcRn 
(SinoBiological) was injected over the antibody surface at 100 nM for 60 s at a flow rate 30 μl/min 
with 90 s dissociation time. All samples were run in PBS-P+ pH 6.0 running buffer and were analysed 
in duplicate. The chip surface was regenerated with 10 mM glycine-HCl pH 2.1.  
For FcRn affinity measurements, VRC01 antibodies were captured on the anti-Fab surface. 
Recombinant human FcRn ectodomains (SinoBiological) were injected over the antibody surface at a 
range of concentrations (12.5 - 800 nM in PBS-P+ pH 6.0) for 40s at a flow rate 30 μl/min and with 
60 s dissociation time. After each injection the antibody surface was regenerated with PBS pH 7.4. 
10 mM glycine-HCl pH 2.1 was used to remove antibodies from the anti-Fab surface. Binding 
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responses at 10s after injection from the double-referenced sensorgrams were selected for affinity 
evaluation using a steady-state affinity model (Biacore™ X100 Evaluation Software). 
Methionine oxidation. 
The heavy and light chains of purified antibody samples were separated by 12% BisTris NuPAGE® 
polyacrylamide gel electrophoresis Heavy chains were excised from the gel and washed three times 
for 15 minutes at RT with 0.1M NH4HCO3 pH 8 and 100% CH3CN (v:v). The samples were dried in a 
SpeedVac centrifuge (Thermo Fisher). After reduction with 0.1M dithiothreitol (DTT) for 45 min at 
56°C and alkylation with 55 mM iodoacetamide (IAA) performed in 0.1M NH4HCO3 pH 8 for 30 min at 
room temperature in the dark, 3 ug of proteomic-grade trypsin was added (Promega) per sample 
and placed at 4°C for30 min prior to overnight incubation at 37°C. The trypsin was inactivated by 
heating for 5 minutes at 100°C. The samples were cooled to RT and digested with 5 ug of 
chymotrypsin (Sigma) for 4h at 37°C. The chymotrypsin was inactivated by heating 5 minutes at 
100°C. After the protease digestions, the gel pieces were incubated in solutions of 50% CH3CN, 5% 
formic acid, 0,1M NH4HCO3, 100% CH3CN and finally in 5% formic acid to extract the resulting 
peptide and glycopeptide mixture. The sample was dried before further analysis by QTOF Agilent 
Technologies LC-Chip MS for high sensitivity nanospray LC MS (Agilent Technologies) as previously 
reported (Vanier et al., 2015). 
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Supplementary Figure Legends: 
Figure S1. Fc glycosylation profiles of the VRC01 antibody (HEK) and its plant-made glycovariants 
(WT, ∆XF, Gal). Deconvoluted mass spectra of tryptic glycopeptides (EEQYNSTYR, 1189.51 Da) 
derived from heavy chain of different VRC01 glycovariants as determined by LC-ESI-MS. Only doubly 
charged ions displayed. Structures of N-glycans that constitute less than 5% of the total population 
have not been illustrated. Glycan cartoons marked with # represent the structure assumed as 
predominant, while abbreviations list both options. N-glycan abbreviations according to the 
ProGlycAn nomenclature. 
Figure S2. Comparisonbetween 1:1 binding interaction and “heterogeneous antibody with 
aglycosylation” modelling for VRC01Gal antibody binding to FcRI. SPR sensorgrams illustrate 
binding and dissociation of antibody-receptor complexes. Data were analysed with either a 1:1 
binding interaction model (left) or a “heterogeneous antibody with aglycosylation model (right).  
Dashed lines denotes maximum responses upon saturation. The results are summarised in the table. 
The 1:1 binding model assumes a reduced maximum response of 50 RU (dark blue lines) and any 
additional binding above that level (black lines) is attributed to a baseline drift (light blue lines). The 
‘heterogeneous antibody with aglycosylation’ model provides a better fit to the data and any 
additional binding above the glycosylated portion of VRC01Gal (pink) is attributed to aglycosylated 
antibodies (light blue), resulting in a proper total maximum response (66 RU). Kinetics and affinity 
parameters for the glycosylated antibodies of the VRC01Gal are not significantly affected by the 
model choice. 
Figure S3. Steady-state affinity measurements of different VRC01 glycovariants bindingFcRIIa. 
During injection of FcRIIa (0.5-8M) over the Protein A captured antibodies, the analytes 
immediately reach a dynamic equilibrium of complex formation and dissociation, which is 
represented by the flat binding shown in the sensorgrams. Responses at steady-states are analysed 
using steady-state affinity evaluation. The Biacore Evaluation software extrapolates affinity values 
which are indicated by a black solid vertical line (when the estimation is robust) or a red dashed line 
(when the estimation is only approximate).  
Figure S4. Steady-state affinity measurements of different VRC01 glycovariants bindingFcRIIb. 
During injection of FcRIIa (0.5-8M) over the Protein A captured antibodies, the analytes 
immediately reach a dynamic equilibrium of complex formation and dissociation, which is 
represented by the flat binding shown in the sensorgrams. Responses at steady-states are analysed 
using steady-state affinity evaluation. The Biacore Evaluation software extrapolates affinity values 
which are indicated by a black solid vertical line (when the estimation is robust) or a red dashed line 
(when the estimation is only approximate).  
Figure S5. Steady-state affinity measurements of different VRC01 glycovariants binding FcRn. Each 
VRC01 glycovariant was captured onto the anti-human Fab surface to the same level, followed by 
injection of recombinant human FcRn ectodomains at different concentrations (800 nM, 400 nM, 
200 nM, 50 nM, 12.5 nM). Since clear steady-state equilibrium responses could not be reached, 
probably due to a presence of receptor dimers causing slow sensorgram upward drifts, the 
responses shortly after injection (as indicated by black crosses) were selected for steady-state 
affinity evaluation. Responses at this time point are believed to represent best 1:1 interaction 
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between FcRn and VRC01 heavy chains, before the dimer-artefacts come into effect. Dashed 
horizontal lines indicate maximum response upon saturation.  
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Table Legends: 
Table 1. Percentage composition of N-glycan populations on the heavy chains of different VRC01 
glycovariants. Structures and abbreviations of N-glycans which constitute less than 5% of the total 
population have been shaded). Unglyc. – unglycosylated heavy chain. Abbreviations according to the 
ProGlycAn nomenclature (http://www.proglycan.com/protein-glycosylation-analysis/nomenclature). 
 
Figure Legends: 
Figure 1. Interaction of VRC01 glycovariants with recombinant human FcγRI and FcγRIIIa. A. SPR 
sensorgrams illustrate binding and dissociation of antibody-receptor complexes. Data were analysed 
with a 1:1 binding interaction model for FcγRI (except VRC01WT, see text for details) and a two-state 
reaction interaction model for FcγRIIIa. Dashed line denotes maximum response upon saturation. 
Theoretical saturation level is displayed separately as a solid line if it differs or could not be 
extrapolated from the data. Receptor concentrations used: FcγRI at 2-240 nM(15-480 nM for 
VRC01aglyco), FcγRIIIa at 125-4000 nM for fucosylated antibodies and 12-800 nM for afucosylated 
ones. Data shown is from one experiment representative of at least two technical repeats. B. Kinetic 
map for the interaction of antibodies with FcγRI based on association rate (on-rate) and dissociation 
rate (off-rate) constants. For VRC01WT, the kinetics parameters of the glycosylated portion were 
used.C. Half-life of the antibody–FcγRI complexes as calculated from the dissociation rate constants. 
Figure 2. Affinity of VRC01 glycovariants to the human FcγRIIa and FcγRIIb. SPR sensorgrams show 
binding responses at the injection of different receptor concentrations (0.5-8 μM) over the Protein 
A-captured antibodies. Dissociation constants are calculated from steady-state responses at a 
dynamic equilibrium of complex formation. Maximum response at the saturation level is marked 
with dashed horizontal lines. When the experimentally-measured response at saturation does not 
overlap with expected response, theoretical saturation levels are indicated with solid horizontal 
lines. Data shown is from one experiment representative of at least two technical repeats. 
Figure 3. Affinity of VRC01 glycovariants to human FcγRs. The graph summarises the affinity values 
(KD) for the interaction of different glycovariants with human FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa. 
Figure 4. Binding of monomeric VRC01 glycovariants to cell surface Fc receptors on THP-1 
monocytes. A. Flow cytometric analysis with FITC-conjugated antibodies specific to FcγRI, FcγRII or 
FcγRIII on the surface of THP-1 cells (red histograms) as compared to the isotype controls (blue 
histograms). The numbers indicate mean fluorescent intensity (MFI) of the populations. B. Binding of 
serially-diluted VRC01 antibodies to THP-1 cells was detected with a FITC-labelled F(ab’)2 fragment 
against human antibodies using flow cytometry. MFI responses were corrected by subtracting 
background response levels from cells incubated with the FITC-labelled F(ab’)2 fragment only (no 
VRC01). Nonlinear regression curve fit was applied. The results represent one of two biological 
repeats. C. FcγRIIIa activation by VRC01WT, VRC01ΔXF and VRC01HEK was demonstrated by luciferase 
activity of ADCC Bioassay Reporter cells. Antibodies were pre-incubated with HIV-1 UG37 gp140 
before effector cells (Jurkat NFAT-luc) were added. Luciferase activity was the average result of 3 
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independent experimental repeats. Error bars equals ±SD and PBS was used as negative control.         
* VRC01ΔXF at 10ug/mL was omitted because the readings exceeded the range of the assay. 
Figure 5. Binding analysis of VRC01 glycovariants to FcRn.A. Human recombinant FcRn ectodomains 
were covalently immobilised on the CM5 sensor chip surface and different VRC01 glycovariants were 
injected at 200 nM concentration in duplicates. Data shown is from one experiment representative 
of at least two technical repeats. Binding and dissociation of different antibodies was observed at pH 
6.0 and the FcRn surface was regenerated with PBS pH 7.4.B. Each VRC01 glycovariant was captured 
onto the anti-human Fab surface to the same level and tested for binding to 200 nM FcRn. 
Sensorgrams represent binding and dissociation at pH 6.0 for two independent repeats. Maximum 
binding level is marked with a dashed horizontal line.   
Figure 6. Methionine oxidation of VRC01 glycovariants.  A. Percentage oxidation of Met252 and 
Met428 on antibody heavy chains, as determined by mass spectrometry. All plant-made VRC01 
glycovariants were produced at the same time under the same conditions and stored in non-
oxidising atmosphere.  Data shown is from one experiment representative of at three biological 
repeats. B. Relative affinity of plant-made VRC01 glycovariants to FcRn compared to VRC01HEK. 
Values obtained from SPR analysis.   
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Figure 1. Interaction of VRC01 glycovariants with recombinant human FcγRI and FcγRIIIa.  
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Figure 2. Affinity of VRC01 glycovariants to the human FcγRIIa and FcγRIIb.   
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Figure 3. Affinity of VRC01 glycovariants to human FcγRs.   
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Figure 4. Binding of monomeric VRC01 glycovariants to cell surface Fc receptors on THP-1 
monocytes.  
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Figure 5.  Binding analysis of VRC01 glycovariants to FcRn.  
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Figure 6. Methionine oxidation of VRC01 glycovariants.  
 
